2-[4-[[4-[bis(2-hydroxyethyl)amino]phenyl]-(4-chlorophenyl)methyl]-N-(2-hydroxyethyl)anilino]ethanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2-[4-[[4-[bis(2-hydroxyethyl)amino]phenyl]-(4-chlorophenyl)methyl]-N-(2-hydroxyethyl)anilino]ethanol
• 化学式: C₂₇H₃₃ClN₂O₄
• 分子量: 485.0
• InChiKey: QCXQLSGBOUUVNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  34
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  87.4
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS
  申请人：PHARMATROPHIX, INC.

  公开号：US20160046559A1

  公开（公告）日：2016-02-18

  Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule.

  提供用于治疗神经和其他疾病的方法和化合物。其中包括向需要治疗的对象施用具有与TrkB受体分子结合和/或调节特异性的化合物的有效量，可选地与TrkA和/或TrkC受体分子结合使用。
• Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
  申请人：The University of North Carolina at Chapel Hill

  公开号：EP2526942A2

  公开（公告）日：2012-11-28

  Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.

  本文提供了治疗神经系统疾病和其他疾病的方法和化合物。其中包括向有需要的受试者施用有效量的对 TrkB 受体分子具有结合和/或调节特异性的化合物。
• EP2526942B1
  申请人：——

  公开号：EP2526942B1

  公开（公告）日：2017-08-09
• EP2581440B1
  申请人：——

  公开号：EP2581440B1

  公开（公告）日：2016-03-16
• NON-HUMAN ANIMALS COMPRISING A HUMANIZED TRKB LOCUS
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US20190159436A1

  公开（公告）日：2019-05-30

  Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.